Gallus BioPharmaceuticals and Roslin Cells Announce an Exclusive Partnership to Supply Cell Therapies for Clients Gallus BioPharmaceuticals, LLC announced a collaboration agreement with Roslin Cells Ltd. to develop and supply clinical and commercial cell therapy products. [Vocus PRW Holdings, LLC.] Press Release Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital Advanced Cell Technology, Inc. announced that it has entered into a $35 million common stock purchase agreement with Lincoln Park Capital Fund, LLC. [Advanced Cell Technology, Inc.] Press Release CureVac Secures €80 Million in Series D Financing CureVac GmbH announced the completion of an €80 million financing round with its main investor, dievini Hopp BioTech Holding. In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer, respectively. [CureVac GmbH] Press Release Parent Project Muscular Dystrophy Awards $280,000 for Cardiac Gene Therapy to University of Missouri Parent Project Muscular Dystrophy announced that it will award the University of Missouri’s Dongsheng Duan, Ph.D. a $280,000 grant to continue his work to treat cardiomyopathy in Duchenne muscular dystrophy through a gene therapy approach. [PR Newswire Association LLC.] Press Release Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® for Hematological Malignancies Gamida Cell announced that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product. NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells. [Gamida Cell] Press Release NewLink Announces an Investigator Initiated Phase II Study of Sipuleucel-T Plus Indoximod in the Treatment of Certain Men with Advanced Prostate Cancer NewLink Genetics announced that it will begin an investigator initiated, randomized, double blind placebo controlled Phase II study entitled “Phase II Study of sipuleucel-T (PROVENGE®) plus indoximod (D-1MT/NLG8189) in the treatment of patients with asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer.” [NewLink Genetics Corporation] Press Release IntelliCell BioSciences Announces Clinical Study for Diabetic Critical Limb Ischemia IntelliCell BioSciences, Inc. announced that it will be initiating a groundbreaking in-human clinical study to treat people who suffer from diabetic induced critical limb ischemia wounds. IntelliCell has developed a proprietary treatment methodology using its autologous cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. [PR Newswire Association LLC.] Press Release RBCC Explores NASA Technology in Stem Cell Search Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), announced that it is exploring the possible use of micro-gravity technology developed by NASA to produce three-dimensional adult stem cells for medical research purposes. [Business Wire] Press Release Flotte Recognized for Leadership in Biomedical Research Terence R. Flotte, MD will be honored by the Massachusetts Society for Medical Research for his leadership in gene therapy research and education. [UMass Medical School] Press Release |